235 related articles for article (PubMed ID: 32249768)
1. FBXO22 degrades nuclear PTEN to promote tumorigenesis.
Ge MK; Zhang N; Xia L; Zhang C; Dong SS; Li ZM; Ji Y; Zheng MH; Sun J; Chen GQ; Shen SM
Nat Commun; 2020 Apr; 11(1):1720. PubMed ID: 32249768
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of FBXO22 inhibits melanoma cell migration, invasion and angiogenesis via the HIF-1α/VEGF pathway.
Zheng Y; Chen H; Zhao Y; Zhang X; Liu J; Pan Y; Bai J; Zhang H
Invest New Drugs; 2020 Feb; 38(1):20-28. PubMed ID: 30887251
[TBL] [Abstract][Full Text] [Related]
3. FBXO22, an epigenetic multiplayer coordinating senescence, hormone signaling, and metastasis.
Johmura Y; Harris AS; Ohta T; Nakanishi M
Cancer Sci; 2020 Aug; 111(8):2718-2725. PubMed ID: 32536008
[TBL] [Abstract][Full Text] [Related]
4. F-box protein FBXO22 mediates polyubiquitination and degradation of KLF4 to promote hepatocellular carcinoma progression.
Tian X; Dai S; Sun J; Jin G; Jiang S; Meng F; Li Y; Wu D; Jiang Y
Oncotarget; 2015 Sep; 6(26):22767-75. PubMed ID: 26087183
[TBL] [Abstract][Full Text] [Related]
5. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21.
Zhang L; Chen J; Ning D; Liu Q; Wang C; Zhang Z; Chu L; Yu C; Liang HF; Zhang B; Chen X
J Exp Clin Cancer Res; 2019 Feb; 38(1):101. PubMed ID: 30808376
[TBL] [Abstract][Full Text] [Related]
6. Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer.
Johmura Y; Maeda I; Suzuki N; Wu W; Goda A; Morita M; Yamaguchi K; Yamamoto M; Nagasawa S; Kojima Y; Tsugawa K; Inoue N; Miyoshi Y; Osako T; Akiyama F; Maruyama R; Inoue JI; Furukawa Y; Ohta T; Nakanishi M
J Clin Invest; 2018 Dec; 128(12):5603-5619. PubMed ID: 30418174
[TBL] [Abstract][Full Text] [Related]
7. FBXO22 Suppresses Metastasis in Human Renal Cell Carcinoma via Inhibiting MMP-9-Mediated Migration and Invasion and VEGF-Mediated Angiogenesis.
Guo F; Liu J; Han X; Zhang X; Lin T; Wang Y; Bai J; Han J
Int J Biol Sci; 2019; 15(3):647-656. PubMed ID: 30745851
[TBL] [Abstract][Full Text] [Related]
8. FBXO22 protein is required for optimal synthesis of the N-methyl-D-aspartate (NMDA) receptor coagonist D-serine.
Dikopoltsev E; Foltyn VN; Zehl M; Jensen ON; Mori H; Radzishevsky I; Wolosker H
J Biol Chem; 2014 Dec; 289(49):33904-15. PubMed ID: 25336657
[TBL] [Abstract][Full Text] [Related]
9. SCF
Bai J; Wu K; Cao MH; Yang Y; Pan Y; Liu H; He Y; Itahana Y; Huang L; Zheng JN; Pan ZQ
Proc Natl Acad Sci U S A; 2019 Jun; 116(24):11754-11763. PubMed ID: 31138683
[TBL] [Abstract][Full Text] [Related]
10. F-Box Protein FBXO22 Mediates Polyubiquitination and Degradation of CD147 to Reverse Cisplatin Resistance of Tumor Cells.
Wu B; Liu ZY; Cui J; Yang XM; Jing L; Zhou Y; Chen ZN; Jiang JL
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28117675
[TBL] [Abstract][Full Text] [Related]
11. FBXO22 mediates polyubiquitination and inactivation of LKB1 to promote lung cancer cell growth.
Zhu XN; He P; Zhang L; Yang S; Zhang HL; Zhu D; Liu MD; Yu Y
Cell Death Dis; 2019 Jun; 10(7):486. PubMed ID: 31217475
[TBL] [Abstract][Full Text] [Related]
12. Neddylation of PTEN regulates its nuclear import and promotes tumor development.
Xie P; Peng Z; Chen Y; Li H; Du M; Tan Y; Zhang X; Lu Z; Cui CP; Liu CH; He F; Zhang L
Cell Res; 2021 Mar; 31(3):291-311. PubMed ID: 33299139
[TBL] [Abstract][Full Text] [Related]
13. Fbxo22 inhibits metastasis in triple-negative breast cancer through ubiquitin modification of KDM5A and regulation of H3K4me3 demethylation.
Li S; He J; Liao X; He Y; Chen R; Chen J; Hu S; Sun J
Cell Biol Toxicol; 2023 Aug; 39(4):1641-1655. PubMed ID: 36112263
[TBL] [Abstract][Full Text] [Related]
14. SCF(Fbxo22)-KDM4A targets methylated p53 for degradation and regulates senescence.
Johmura Y; Sun J; Kitagawa K; Nakanishi K; Kuno T; Naiki-Ito A; Sawada Y; Miyamoto T; Okabe A; Aburatani H; Li S; Miyoshi I; Takahashi S; Kitagawa M; Nakanishi M
Nat Commun; 2016 Feb; 7():10574. PubMed ID: 26868148
[TBL] [Abstract][Full Text] [Related]
15. Global identification of phospho-dependent SCF substrates reveals a FBXO22 phosphodegron and an ERK-FBXO22-BAG3 axis in tumorigenesis.
Liu P; Cong X; Liao S; Jia X; Wang X; Dai W; Zhai L; Zhao L; Ji J; Ni D; Liu Z; Chen Y; Pan L; Liu W; Zhang J; Huang M; Liu B; Tan M
Cell Death Differ; 2022 Jan; 29(1):1-13. PubMed ID: 34215846
[TBL] [Abstract][Full Text] [Related]
16. FBXO22, ubiquitination degradation of PHLPP1, ameliorates rotenone induced neurotoxicity by activating AKT pathway.
Zheng X; Yu S; Xue Y; Yan F
Toxicol Lett; 2021 Oct; 350():1-9. PubMed ID: 34182063
[TBL] [Abstract][Full Text] [Related]
17. The nuclear affairs of PTEN.
Planchon SM; Waite KA; Eng C
J Cell Sci; 2008 Feb; 121(Pt 3):249-53. PubMed ID: 18216329
[TBL] [Abstract][Full Text] [Related]
18. Fbxo22 promotes cervical cancer progression via targeting p57
Lin M; Zhang J; Bouamar H; Wang Z; Sun LZ; Zhu X
Cell Death Dis; 2022 Sep; 13(9):805. PubMed ID: 36127346
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-21 (Mir-21) Promotes Cell Growth and Invasion by Repressing Tumor Suppressor PTEN in Colorectal Cancer.
Wu Y; Song Y; Xiong Y; Wang X; Xu K; Han B; Bai Y; Li L; Zhang Y; Zhou L
Cell Physiol Biochem; 2017; 43(3):945-958. PubMed ID: 28957811
[TBL] [Abstract][Full Text] [Related]
20. FBXO22 Accelerates Pancreatic Cancer Growth by Deactivation of the Hippo Pathway via Destabilizing LATS2.
Ma J; Wu Y; Cheng S; Yang W; Zhong L; Li Q; Fang L
Dig Dis Sci; 2023 May; 68(5):1913-1922. PubMed ID: 36515852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
